Vertex Pharmaceuticals Incorporated (VRTX) : Zacks Investment Research ranks Vertex Pharmaceuticals Incorporated (VRTX) as 3, which is a Hold recommendation. 9 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 2 other analysts are mildly bullish on the stock and favor a Buy. A total of 5 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 16 research analysts is 1.72, which indicates as a Buy.
Vertex Pharmaceuticals Incorporated (VRTX) stock is expected to deviate a maximum of $22.17 from the average target price of $115.75 for the short term period. 12 Street Experts have initiated coverage on the stock with the most promising target being $155 and the most muted being $75.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $86.16 and $85.92 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $89.90. The buying momentum continued till the end and the stock did not give up its gains. It closed at $89.66, notching a gain of 3.64% for the day. The total traded volume was 1,705,293 . The stock had closed at $86.51 on the previous day.
Also, In the latest statement by the brokerage house, Goldman Sachs downgrades its outlook on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). The current rating of the shares is Neutral, according to the research report released by the firm. Previously, the company had a rating of Buy. The brokerage firm lowers the price target from $109 per share to $88 per share. The rating by the firm was issued on April 28, 2016. The company shares have dropped -28.82% from its 1 Year high price. On Aug 10, 2015, the shares registered one year high at $143.45 and the one year low was seen on Mar 17, 2016. The 50-Day Moving Average price is $88.30 and the 200 Day Moving Average price is recorded at $90.50.
Vertex Pharmaceuticals Incorporated (Vertex) is a global biotechnology company. The Company is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs. The Company uses precision medicine approaches to create transformative drugs for patients with serious diseases in specialty markets. Vertexs business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF). It is also engaged in other research and early-stage development programs, including programs in the areas of oncology and neurology. The Companys product candidates include KALYDECO (ivacaftor), Lumacaftor in combination with Ivacaftor, VX-661 in combination with Ivacaftor, VX-803, VX-970 and VX-222. The Companys product KALYDECO is available in the market.